VSTM - Verastem, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.5900
+0.1000 (+6.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.4900
Open1.4900
Bid0.0000 x 4000
Ask0.0000 x 2200
Day's Range1.4600 - 1.5900
52 Week Range1.1600 - 10.3500
Volume1,120,155
Avg. Volume2,204,788
Market Cap117.464M
Beta (3Y Monthly)2.53
PE Ratio (TTM)N/A
EPS (TTM)-1.5830
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.83
Trade prices are not sourced from all markets
  • Business Wire16 days ago

    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 104,000 shares of its common stock to five new employees. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $1.41 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on July 1, 2019 and vest at a rate of 25% on the one-year anniversary of his or her date of hire, and thereafter, at a rate of 6.25% of the shares subject to the options at the end of each successive three-month period, provided that the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.

  • Hedge Funds Have Never Been This Bullish On Verastem Inc (VSTM)
    Insider Monkey23 days ago

    Hedge Funds Have Never Been This Bullish On Verastem Inc (VSTM)

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged during the first quarter. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 40% and 25% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted […]

  • Verastem Up on Positive Data From Early-Stage Copiktra Study
    Zacks25 days ago

    Verastem Up on Positive Data From Early-Stage Copiktra Study

    Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.

  • Benzinga28 days ago

    Verastem Shares Response Rate From COPIKTRA Data

    Verastem Oncology (NASDAQ: VSTM ) presented COPIKTRA data showing response rates of 44% to 57%, including complete response rates of 15% to 22% in patients with relapsed or refractory peripheral T-cell ...

  • Business Wire28 days ago

    Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on Malignant Lymphoma

    Steven Horwitz, MD, Gives Oral Presentation Highlighting Phase 1 Duvelisib Data in Patients with Relapsed or Refractory PTCL

  • The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
    Zacks29 days ago

    The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure

    The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure

  • Business Wire29 days ago

    Verastem Oncology Announces Leadership Changes

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Robert Forrester has decided to step down as President and Chief Executive Officer. Mr. Forrester has agreed to continue serving Verastem Oncology in an advisory capacity.

  • Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal
    Zackslast month

    Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

    A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.

  • Business Wirelast month

    Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting

    In CLL/SLL Patients in the DUO Study, Duvelisib Treatment Rapidly Increased Lymphocytes and Resulted in Shrinkage of Lymph Nodes, With 86% of Patients Achieving a Lymph Node Respon

  • Business Wire2 months ago

    Verastem Oncology to Present at the Jefferies 2019 Global Healthcare Conference

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 11:30 a.m. EDT in New York, NY. A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. Verastem Oncology (VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer.

  • Did You Manage To Avoid Verastem's (NASDAQ:VSTM) Devastating 85% Share Price Drop?
    Simply Wall St.2 months ago

    Did You Manage To Avoid Verastem's (NASDAQ:VSTM) Devastating 85% Share Price Drop?

    We're definitely into long term investing, but some companies are simply bad investments over any time frame. We...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of VSTM earnings conference call or presentation 9-May-19 8:30pm GMT

    Q1 2019 Verastem Inc Earnings Call

  • Business Wire2 months ago

    Verastem Oncology to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 20th Annual B. Riley FBR Institutional Investor Conference on Thursday, May 23, 2019 at 1:30 p.m. PDT in Beverly Hills, CA. A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. Verastem Oncology (VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer.

  • Business Wire2 months ago

    Verastem Oncology to Present New COPIKTRA™ (Duvelisib) Dose Modification Data from Patients Treated in the Phase 3 DUO Study

    Abstract Highlights the Effect of Dose Modification on Response to COPIKTRA in Adult Patients with CLL/SLL After At Least Two Prior Therapies

  • Verastem Inc (VSTM) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Verastem Inc (VSTM) Q1 2019 Earnings Call Transcript

    VSTM earnings call for the period ending March 31, 2019.

  • Verastem (VSTM) Reports Q1 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Verastem (VSTM) Reports Q1 Loss, Lags Revenue Estimates

    Verastem (VSTM) delivered earnings and revenue surprises of -10.87% and -41.16%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Verastem: 1Q Earnings Snapshot

    On a per-share basis, the Needham, Massachusetts-based company said it had a loss of 52 cents. Losses, adjusted for amortization costs, came to 51 cents per share. The results did not meet Wall Street ...

  • Business Wire2 months ago

    Verastem Oncology Reports First Quarter 2019 Financial Results

    Company Reports $1.7 Million in Net Product Revenues from COPIKTRA™; Issues Product Revenue Guidance for 2019

  • Business Wire3 months ago

    Verastem Oncology to Announce First Quarter 2019 Financial Results and Corporate Update on May 9, 2019

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will host a conference call and webcast on Thursday, May 9, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2019. The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the Company's website at www.verastem.com. A replay of the webcast will be archived on the Company's website for 90 days following the call.

  • Business Wire3 months ago

    Verastem Oncology Announces Amendment to Refinance Hercules Loan Facility

    Verastem, Inc. (VSTM) operating as Verastem Oncology, (or the “Company”), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced its entry into an amendment (the “Fourth Amendment”) to its existing Loan and Security Agreement with Hercules Capital, Inc. (HTGC) (“Hercules”), changing certain terms of the agreement and increasing the borrowing limit from $50 million to $75 million in financing. The increased loan facility proceeds will be available for the ongoing launch of COPIKTRA™ in the U.S., the Company’s other ongoing development programs, and for general corporate purposes, subject to certain conditions of funding.

  • Business Wire4 months ago

    Verastem Oncology to Present at the H.C. Wainwright Global Life Sciences Conference

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9, 2019 at 11:50 a.m. BST in London, UK. A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. Verastem Oncology (VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of VSTM earnings conference call or presentation 12-Mar-19 8:30pm GMT

    Q4 2018 Verastem Inc Earnings Call

  • 3 Penny Stocks That Could Make You Rich -- or Regretful
    Motley Fool4 months ago

    3 Penny Stocks That Could Make You Rich -- or Regretful

    These three penny stocks have enormous upside potential, but they each come with a hefty dose of risk.

  • Why Verastem Stock Broke Down Today
    Motley Fool4 months ago

    Why Verastem Stock Broke Down Today

    Verastem's new oncology drug isn't setting the world on fire.